On Jul 13, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation BSX . The stock currently carries a Zacks Rank #2 (Buy).
We are currently looking forward to the company’s recently introduced global restructuring plan, the execution of which will result in the fulfillment of its margin leverage goals and help produce low-to-mid-teens EPS growth, ahead of the industry average.
Without revealing much detail, the company noted that the program will focus on developing global commercialization, technology and manufacturing capabilities in key growth markets, continuing implementation of its Plant Network Optimization (PNO) strategy, and expanding operational efficiencies to support its operating income margin goals.
